In addition to costs associated with DM treatment (costs of insulin and antidiabetic drugs, hypoglycaemia hospitalisation, etc.), treatment of immediate and distant future complications caused by DM should be taken into consideration. This evidence concerns the gene INS and diabetes mellitus.